Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Inventory (2016 - 2025)

Guided Therapeutics' Inventory history spans 15 years, with the latest figure at $583000.0 for Q3 2025.

  • For Q3 2025, Inventory fell 8.33% year-over-year to $583000.0; the TTM value through Sep 2025 reached $583000.0, down 8.33%, while the annual FY2024 figure was $633000.0, 0.16% changed from the prior year.
  • Inventory for Q3 2025 was $583000.0 at Guided Therapeutics, down from $595000.0 in the prior quarter.
  • Across five years, Inventory topped out at $648000.0 in Q3 2023 and bottomed at $548000.0 in Q4 2022.
  • The 5-year median for Inventory is $596000.0 (2022), against an average of $603315.8.
  • The largest annual shift saw Inventory skyrocketed 1137.25% in 2021 before it decreased 9.83% in 2022.
  • A 5-year view of Inventory shows it stood at $571000.0 in 2021, then decreased by 4.03% to $548000.0 in 2022, then rose by 15.33% to $632000.0 in 2023, then rose by 0.16% to $633000.0 in 2024, then dropped by 7.9% to $583000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Inventory are $583000.0 (Q3 2025), $595000.0 (Q2 2025), and $633000.0 (Q1 2025).